CD52 Antigen

A small GPI-linked glycoprotein expressed on the surface of normal and malignant B-CELLS; T-CELLS; MONOCYTES; MACROPHAGES; NK CELLS; and GRANULOCYTES. It is expressed densely and without modulation in many malignant T-cell neoplasms and therefore a target for antibody therapies (e.g., ALEMTUZUMAB).

Also Known As:

CD52 Protein; CDw52 Antigen; Cambridge Pathology 1 Antigen; Campath-1 Antigen; Campath-1 Receptor; Campath-1H Antigen; HLA-Bw52; HLA-Bw52 Antigen; Lymphocyte Antigen CD52; Lymphocyte Antigen CDw52; CD52, Lymphocyte Antigen; CDw52, Lymphocyte Antigen; Campath 1 Antigen; Campath 1 Receptor; Campath 1H Antigen; HLA Bw52; HLA Bw52 Antigen

Networked: 40 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Adamec, Ivan: 2 articles (01/2022 - 11/2020)
2.	Habek, Mario: 2 articles (01/2022 - 11/2020)
3.	Rizzieri, David A: 2 articles (05/2011 - 02/2002)
4.	Annovazzi, Pietro Osvaldo Luigi: 1 article (01/2022)
5.	Bardina, Valentina: 1 article (01/2022)
6.	Clerico, Marinella: 1 article (01/2022)
7.	Cocco, Eleonora: 1 article (01/2022)
8.	De Mercanti, Stefania Federica: 1 article (01/2022)
9.	Horakova, Dana: 1 article (01/2022)
10.	Maglione, Alessandro: 1 article (01/2022)

Related Diseases

1.	Relapsing-Remitting Multiple Sclerosis 11/01/2020 - "Alemtuzumab is a humanized monoclonal antibody targeting CD52 protein that has shown great efficacy in the treatment of relapsing remitting multiple sclerosis and is associated with prolonged remission of the disease. " 12/01/2018 - "Alemtuzumab is a monoclonal antibody targeting the CD52 antigen used in the treatment of relapsing-remitting multiple sclerosis (RRMS). " 01/01/2017 - "Alemtuzumab is a selective humanized monoclonal antibody directed against the CD52 antigen, and has been found to be a powerful treatment for relapsing remitting multiple sclerosis. "
2.	Multiple Sclerosis 07/01/1996 - "In a pilot study, seven patients with multiple sclerosis were treated with CAMPATH-IH which targets the CD52 antigen present on lymphocytes and monocytes. " 02/01/1996 - "Fourteen patients with multiple sclerosis were treated with the humanized monoclonal antibody CAMPATH-1H which targets the CD52 antigen present on all lymphocytes and some monocytes; four also received anti-CD4 antibody. " 01/01/2022 - "Alemtuzumab is highly effective in the treatment of patients with relapsing multiple sclerosis (PwRMS) and selectively targets the CD52 antigen, with a consequent profound lymphopenia, particularly of CD4+ T lymphocytes. "
3.	Lymphopenia (Lymphocytopenia) 01/01/2022 - "Alemtuzumab is highly effective in the treatment of patients with relapsing multiple sclerosis (PwRMS) and selectively targets the CD52 antigen, with a consequent profound lymphopenia, particularly of CD4+ T lymphocytes. " 01/01/2013 - "Alemtuzumab (previously known as Campath(®)) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and subsequent modification of the immune repertoire. "
4.	Takayasu Arteritis (Arteritis, Takayasu's) 03/01/1983 - "Recent studies on the pathogenesis of Takayasu disease have focussed on the participation of genetic factors, and HLA analysis has confirmed the close relationship between Takayasu disease and HLA Bw52. " 01/01/1994 - "The presence of HLA-Bw52 or B5 is closely associated with Takayasu arteritis in all 3 Asian countries. " 01/01/1992 - "The presence of HLA-Bw52, however, might have a close association with Takayasu arteritis in Korea as well as in Japan. " 10/01/1978 - "HLA-Bw52 in Takayasu disease." 01/01/1992 - "Left ventricular dysfunction and HLA Bw52 antigen in Takayasu arteritis."
5.	Rheumatoid Arthritis 12/01/1996 - "Nine patients with refractory rheumatoid arthritis (RA) fulfilling ARA criteria, and one with ankylosing spondylitis (AS) received a human IgG4 Campath-1 MoAb (with specificity against the pan-lymphocyte antigen CD52) as part of a two-stage therapeutic protocol. " 05/01/1996 - "Patients with severe rheumatoid arthritis who had failed treatment with conventional therapies were treated with a course of five or 10 daily intravenous infusions of CAMPATH-1H, a humanized antibody against the CD52 antigen, resulting in profound depletion of peripheral blood mononuclear cells. " 04/05/1997 - "CAMPATH-1H is a recombinant humanized murine monoclonal immunoglobulin (IgG1) which recognizes the CDw52 antigen of human lymphocytes, and has been the subject of clinical trials for the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis. "

Related Drugs and Biologics

1.	Alemtuzumab (Campath)
2.	Monoclonal Antibodies
3.	Immunoglobulin G (IgG)
4.	Immunoglobulins (Immunoglobulin)
5.	Therapeutic Uses
6.	HLA-DR2 Antigen (HLA DR2 Antigen)
7.	Talc
8.	Prodrugs
9.	Prednisone (Sone)
10.	Methotrexate (Mexate)

Related Therapies and Procedures

1.	Stem Cell Transplantation
2.	Therapeutics
3.	Drug Therapy (Chemotherapy)
4.	Pleurodesis
5.	Intravenous Infusions